Open AccessHistological Subtypes and Response to PD-1/PD-L1 Blockade in Advanced Urothelial Cancer: A Retrospective Study
Author(s) -
Natalie J. Miller,
Ali Raza Khaki,
Leonidas Diamantopoulos,
Mehmet Asım Bilen,
Víctor Sacristán Santos,
Neeraj Agarwal,
Rafael Morales-Bárrera,
Michael Devitt,
Ariel Ann Nelson,
Christopher J. Hoimes,
Evan Shreck,
Hussein Assi,
Benjamin A. Gartrell,
Alex Sankin,
Alejo RodríguezVida,
Mark P. Lythgoe,
David J. Pinato,
Alexandra Drakaki,
Monika Joshi,
Pedro Isaacsson Velho,
Noah M. Hahn,
Sandy Liu,
Lucía Alonso Buznego,
Ignacio Durán,
Marcus W. Moses,
Jayanshu Jain,
Jure Murgić,
Pedro Barata,
Abhishek Tripathi,
Yousef Zakharia,
Matthew D. Galsky,
Guru Sonpavde,
Evan Y. Yu,
Gary H. Lyman,
Petros Grivas
Publication year - 2020
Publication title -
the journal of urology/the journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.402
H-Index - 256
eISSN - 1527-3792
pISSN - 0022-5347
DOI - 10.1097/ju.0000000000000761
Subject(s) - medicine , miller , library science , gerontology , biology , ecology , computer science
Urinary tract cancer can be pure urothelial carcinoma, pure nonurothelial carcinoma or variant urothelial carcinoma (defined here as mixed urothelial carcinoma). Little is known regarding outcomes for patients with variant urothelial carcinoma receiving immune checkpoint inhibitors. We hypothesized that variant urothelial carcinoma does not compromise immune checkpoint inhibitor efficacy in patients with advanced urothelial carcinoma.